News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

YiSheng BioPharma To Collaborate With The Scripps Research Institute On AIDS Vaccine



11/8/2016 10:58:34 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Yisheng Biopharma, a Beijing vaccine company, will collaborate with San Diego's The Scripps Research Institute on a next-gen AIDS vaccine. Yisheng will contribute its PIKA vaccine adjuvant to a TSRI-developed vaccine consisting of novel gp140 trimers and self-assembling nanoparticles. TSRI scientists will also evaluate the potential of PIKA adjuvant for AIDS vaccine candidates. The PIKA adjuvant, a Toll-Like Receptor 3 (TLR3) agonist, has been tested in Phase I clinical trials for hepatitis B and Phase II trials for rabies, with promising results, according to Yisheng.

Read at ChinaBio Today


comments powered by Disqus
   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES